BrainStorm Cell Therapeutics Inc (BCLI): Patients who have benefited from company...

Reply Private New

Next 10 Prev Next

Send PM Follow Ignore

Followers	7
Posts	561
Boards Moderated	0
Alias Born	04/09/2018

Chief-money

Re: None

Wednesday, 01/08/2020 4:14:26 PM

Wednesday, January 08, 2020 4:14:26 PM

Patients who have benefited from company’s NurOwn treatment that’s in ALS phase 3 and MS phase 2 trials. $BCLI

https://farmstrong.info/2019/08/20/maras-list-of-nurown-responders/

Keep Last Read

Next 10 Prev Next

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:

Detailed Quote

Recent BCLI News

Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 09/17/2024 07:32:09 PM
Form 8-K - Current report • Edgar (US Regulatory) • 09/16/2024 08:36:41 PM
Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 09/09/2024 04:15:04 AM
Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 08/28/2024 09:01:02 PM
Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 08/16/2024 11:00:19 AM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 12:01:59 PM
Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 11:15:21 AM
Form PRER14A - Preliminary Proxy Soliciting materials • Edgar (US Regulatory) • 08/06/2024 08:59:18 PM
Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 08/05/2024 09:11:53 PM
Form 8-K - Current report • Edgar (US Regulatory) • 07/30/2024 08:05:27 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/24/2024 08:05:18 PM
BCLI Update - Progress Supports Our 10x Plus Value Range Potential • PR Newswire (Canada) • 07/24/2024 12:30:00 PM
BCLI Update - Progress Supports Our 10x Plus Value Range Potential • PR Newswire (US) • 07/24/2024 12:30:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 07/19/2024 08:05:57 PM
Initiation - Potential 10x Return on Successful Phase 3b. Promising Post Hoc and Biomarker Analysis Underpins Our NurOwn® Clinical Effectiveness Expectation • PR Newswire (US) • 06/14/2024 04:01:00 PM
Initiation - Potential 10x Return on Successful Phase 3b. Promising Post Hoc and Biomarker Analysis Underpins Our NurOwn® Clinical Effectiveness Expectation • PR Newswire (Canada) • 06/14/2024 04:01:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 10:05:20 AM

More BCLI News

InvestorsHub NewsWire

FEATURED Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • Sep 18, 2024 10:29 AM

Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM

PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM

North Bay Resources Announces Mt. Vernon Gold Mine Bulk Sample, Sierra County, California • NBRI • Sep 11, 2024 9:15 AM

One World Products Issues Shareholder Update Letter • OWPC • Sep 11, 2024 7:27 AM

Kona Gold Beverage Inc. Reports $1.225 Million in Revenue and $133,000 Net Profit for the Quarter • KGKG • Sep 10, 2024 1:30 PM

Start posting your company's news

Only $200 per official company press release!

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover